Kiniksa Pharmaceuticals Ltd., of Hamilton, Bermuda, said the underwriters of its IPO exercised their option to purchase an additional 1 million class A common shares at $18 each, bringing the total sold to 9.48 million for gross proceeds of approximately $170.7 million.